Should I avoid plastic food containers?

A proportionate version, yes — especially with heat. Migration of bisphenols and plasticisers into food rises steeply with temperature, fat content and container age, so the highest-yield habits are: do not microwave or hot-fill in plastic, use glass or ceramic for hot and fatty foods, discard scratched and clouded plastic, and rely less on canned food where linings contain bisphenols. Intervention studies show such changes measurably lower urinary biomarkers within days. What this is not is protection against demonstrated harm — it is cheap precaution against a plausible, unresolved one, which is the honest framing.

Frequently it means bisphenol S or F — molecules so structurally similar to BPA that they show comparable estrogenic activity in laboratory assays, with far less toxicological and biomonitoring data. Human BPS levels have risen as BPA fell: a documented regrettable substitution. 'BPA-free' is a marketing statement about one molecule, not a safety finding about the replacement. If the goal is avoiding bisphenols as a class, the effective moves are material-level — glass, stainless steel, ceramic — rather than label-level. The same lesson applies to phthalate-free plasticisers.

Are endocrine disruptors causing infertility and falling sperm counts?

The sperm-decline literature itself is contested — the influential meta-analyses reporting a halving over decades face serious criticisms about counting methods, laboratory standardisation and selection of historical data, and fertility trends are dominated by delayed childbearing. Prenatal phthalate exposure shows some of the more consistent associations with male reproductive endpoints, and the hypothesis is taken seriously by professional endocrinology. The defensible summary: a plausible contributing factor with suggestive human evidence, far from demonstrated as a driver of population fertility — and anyone selling certainty in either direction is ahead of the data.

What should pregnant women actually do?

Focus precaution where the biology says the stakes are highest, without inflating anxiety. Practical measures with biomarker evidence behind them: minimise heating food in plastic and heavy canned-food reliance; prefer fresh over ultra-processed food (which also carries independent benefits); moderate use of strongly fragranced cosmetics and air fresheners (fragrance mixtures carry phthalates); wash hands after handling thermal-paper receipts; ventilate and wet-dust the home. None of this requires purchasing anything, which distinguishes evidence-proportionate advice from the detox economy that monetises the same worry.

Why do European and American regulators disagree so dramatically?

Because the underlying science underdetermines the answer, and the remaining distance is filled by regulatory philosophy. European assessment gives more weight to sensitive non-guideline academic studies and to precaution under uncertainty; US assessment privileges guideline-compliant studies with predefined endpoints and blinded analysis. On BPA those philosophies produced conclusions four orders of magnitude apart from the same literature — with the EMA and BfR dissenting even within Europe. For the public the useful lesson is that a regulatory limit is a risk-management decision, not a measured property of the molecule.

Is endocrine disruption just another chemical scare?

No — it is the chemical scare category's one member with a proven human catastrophe at its foundation. DES demonstrated that a hormonally active exposure in pregnancy can cause cancer and malformation in the next generation; high-dose pesticide and industrial exposures have caused reproductive harm; the mechanistic biology is orthodox endocrinology. What remains genuinely unsettled is the population-scale effect of everyday low-dose mixtures — a hard, active, legitimate science. The field is damaged from both flanks: by dismissal that ignores DES, and by advocacy that attributes every modern trend to plastics. The evidence supports neither.

Home › Topics › Endocrine Disruptors

Endocrine Disruptors

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Endocrine-disrupting chemicals (EDCs) — substances that interfere with hormone systems, from bisphenol A and phthalates to certain pesticides and flame retardants — occupy the most genuinely unsettled territory in environmental health: the phenomenon is unambiguously real, the population-level magnitude is unresolved, and the world’s major regulators openly disagree with each other. The clearest illustration is bisphenol A, for which EFSA cut its tolerable daily intake twenty-thousand-fold in 2023 — a decision the European Medicines Agency and Germany’s BfR formally disputed, while the US FDA maintains that current exposures are safe. Between the settled history (diethylstilbestrol proved that hormonally active chemicals can devastate a generation) and the unsupported extreme (that trace plastics exposure explains every modern disease trend) lies a large, active and legitimately contested science (WHO/UNEP: State of the Science of Endocrine Disrupting Chemicals).

Key messages

SETTLED: the phenomenon is real

That exogenous chemicals can disrupt hormone systems and cause human disease is proven history, not hypothesis. Diethylstilbestrol (DES), prescribed to millions of pregnant women until the 1970s, caused vaginal clear-cell adenocarcinoma and reproductive tract malformations in daughters exposed in utero — the founding tragedy of the field and permanent proof that developmental windows are exquisitely hormone-sensitive. High-dose occupational and accidental exposures to several pesticides and industrial chemicals have demonstrated reproductive and thyroid effects. The concept of endocrine disruption is as sound as any in toxicology.

GENUINELY OPEN: population effects at everyday exposure levels

The unresolved question is whether the low, chronic, mixed exposures of ordinary life — bisphenols from can linings and receipts, phthalates from soft plastics and cosmetics, residues of certain pesticides — produce measurable disease at population scale. Observational epidemiology reports associations with reduced semen quality, earlier puberty, obesity, neurodevelopmental outcomes and infertility, but exposure measurement is hard (many EDCs clear in hours), confounding is pervasive, and effect sizes are small. This is a legitimately contested scientific frontier, not a settled harm and not a debunked scare.

THE REGULATORS THEMSELVES DISAGREE: the BPA schism

Bisphenol A produced the most instructive spectacle in modern regulatory science: in 2023 EFSA cut its tolerable daily intake by a factor of twenty thousand — from 4 micrograms to 0.2 nanograms per kilogram per day — based on immune-cell changes in rodent studies, instantly rendering essentially all European exposure 'excessive'. The European Medicines Agency and Germany's BfR formally disputed the methodology; the US FDA maintains current exposures are safe. When expert agencies reviewing the same literature diverge by four orders of magnitude, the honest conclusion is that the science genuinely underdetermines the answer and the difference lies in precautionary philosophy. The EU proceeded to ban BPA in food-contact materials from 2025.

GENUINELY OPEN AND METHODOLOGICALLY HARD: low-dose and non-monotonic effects

The field's central theoretical claim — that hormonally active chemicals can produce effects at low doses that testing at high doses misses, sometimes with non-monotonic (U-shaped) dose-response — is biologically plausible, since hormones themselves act at picomolar concentrations, but has proven stubbornly difficult to replicate to regulatory standards. The dedicated US CLARITY-BPA programme, designed jointly by academic and regulatory scientists to resolve exactly this, produced results each side reads as vindication. Whether standard toxicology systematically misses endocrine effects remains the deepest open question in chemical regulation.

UNSUPPORTED: EDCs as the master explanation, and detox as the remedy

The claim that endocrine disruptors are the driver of falling sperm counts, the obesity epidemic, gender identity or civilisational decline outruns the evidence — each of those phenomena has stronger or equally strong competing explanations, and the sperm-count decline itself remains contested measurement science. Equally unsupported: hormone 'detox' regimens, and marketing that swaps BPA for structurally near-identical bisphenols S and F, which share estrogenic activity in laboratory assays — 'BPA-free' is frequently regrettable substitution with a label.

What is defensible now

Because the exposures are ubiquitous and the questions open, proportionate precaution focused on the highest-plausibility windows is rational: pregnancy and early childhood. Practical, cost-free measures — not heating food in plastic, less canned and ultra-processed food, fewer fragranced cosmetics during pregnancy, ventilating and damp-dusting homes — reduce biomarker levels demonstrably in intervention studies. Professional societies including the Endocrine Society endorse exactly this posture: take the science seriously, target developmental windows, and avoid both dismissal and panic.

Key statistics

20,000-fold

EFSA reduction of the BPA tolerable daily intake in 2023 — from 4 µg to 0.2 ng/kg bw/day

EFSA

2 agencies

EMA and Germany’s BfR formally disputed the EFSA 2023 BPA opinion — an open regulatory schism

EMA/BfR

2025

EU ban on bisphenol A in food-contact materials enters into force with transition periods

European Commission

Hours

biological half-life of BPA and most phthalates — why single spot-urine studies measure exposure poorly

Pharmacokinetics

~800

chemicals identified by WHO/UNEP as known or suspected of interfering with hormone receptors or synthesis

WHO/UNEP 2012

DES

diethylstilbestrol — the proven case: in-utero exposure caused cancer and malformations in the next generation

Historical record

Endocrine disruptors — where the disagreement actually lies

Source: Bars show strength of supporting evidence. High values indicate well-supported propositions; low values indicate claims tested and not supported.

Glossary of key terms

Diethylstilbestrol — the founding tragedy
HistoryDES, a synthetic oestrogen prescribed from the 1940s to prevent miscarriage (for which it never worked), was linked in 1971 to vaginal clear-cell adenocarcinoma in young women exposed in utero — the first proof that a hormonal exposure in pregnancy could cause cancer in the next generation. DES daughters also carry excess reproductive malformations and pregnancy complications; effects in grandchildren are under study. Every element of modern EDC science descends from this case: the developmental-window concept, the long latency, the transgenerational worry, and the permanent rebuttal to the claim that hormonally active chemicals in pregnancy are a hypothetical concern.

The developmental window hypothesis
MechanismHormones orchestrate development: brief signals at precise fetal and infant stages determine reproductive tract architecture, brain sexual differentiation, metabolic set-points. The field's organising idea is that interference during these windows can cause permanent effects invisible at the time and unrepairable later — effects that the same exposure in an adult would not produce. This is why EDC epidemiology concentrates on pregnancy cohorts, why regulatory fights centre on infant products (the EU banned BPA in baby bottles back in 2011), and why proportionate advice targets pregnant women rather than the whole population. The hypothesis is mechanistically solid; quantifying its real-world magnitude is the open part.

The EFSA-EMA-FDA divergence on BPA
Regulatory scienceEFSA's 2023 re-evaluation keyed its tolerable daily intake to a subtle immunological endpoint — an increase in Th17 cell percentage in mouse studies — and applied large uncertainty factors, landing at 0.2 ng/kg/day. The EMA objected that the endpoint's human relevance and adversity were unestablished; BfR published a diverging opinion proposing a value orders of magnitude higher; the US FDA, weighting guideline-compliant studies including CLARITY-BPA core data, maintains current dietary exposure is safe. Nothing better illustrates that regulatory toxicology contains value judgments — endpoint selection, uncertainty factors, study weighting — inside what is presented as pure science. The EU legislated the precautionary reading into a food-contact ban regardless.

Phthalates and anti-androgen syndrome
ToxicologyCertain phthalates (DEHP, DBP) are established anti-androgens in rodents, producing the 'phthalate syndrome' of male reproductive malformations at high doses, and human cohort studies associate higher prenatal phthalate exposure with reduced anogenital distance in male infants — one of the more consistent low-dose human findings in the field, though effect sizes are small and causality debated. Several phthalates are restricted in EU toys, cosmetics and food-contact uses. They also illustrate the substitution treadmill: restricted phthalates were replaced by other plasticisers (DINCH, DEHT, and other phthalates) with thinner data — the same pattern as BPA to BPS.

CLARITY-BPA and the replication problem
EvidenceCLARITY-BPA was a purpose-built US attempt to end the low-dose war: a guideline-compliant two-year core study run by the FDA's National Center for Toxicological Research, paired with academic investigator studies on the same exposed animals. The core study found no consistent adverse effects at human-relevant doses; several academic arms reported effects at low doses, notably on mammary gland and brain. Each camp declared victory, disputing which arm's methods should carry weight — blinding and predefined endpoints versus sensitive non-guideline measures. The programme resolved little but clarified precisely where the disagreement lives: not in the data, but in which kinds of data count.

Mixtures and the 'something from nothing' problem
Exposure scienceHumans carry dozens of hormonally active chemicals simultaneously, each typically below its individual effect threshold. Experimental work shows that combinations of anti-androgens each at no-effect doses can jointly produce effects — 'something from nothing' — because they act on a shared pathway additively. Regulation, however, assesses chemicals one at a time; mixture risk assessment remains largely aspirational (the EU has committed to a mixture assessment factor in principle). This is arguably the strongest scientifically grounded criticism the EDC field makes of the current system, and it applies to far more than endocrine endpoints.